| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | 0.22 | 3e-08 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | 0.23 | 3e-08 |
| mRNA | SNX-2112 | GDSC1000 | pan-cancer | AAC | 0.18 | 3e-08 |
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | 0.23 | 4e-08 |
| mRNA | FK866 | CTRPv2 | pan-cancer | AAC | 0.23 | 4e-08 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | 0.19 | 4e-08 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.29 | 7e-08 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | 0.28 | 9e-08 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | 0.18 | 9e-08 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.19 | 9e-08 |